ZTS Zoetis Inc. Insider Trading

Board member Frank Damelio makes first open-market purchase at ZTS, buying substantial stake while stock trades well below 52-week high.

Frank Damelio, a Zoetis board director, has made his first open-market share purchase in at least three years, acquiring a meaningful stake equal to nearly half his existing holdings. This stands out because Damelio's prior Form 4 activity was entirely stock-based compensation (option exercises and grants); he's now using personal capital to buy shares, which is a distinct signal compared to passively receiving compensation. The purchase comes as the stock trades significantly below its 52-week high and has declined sharply over recent months, meaning Damelio is buying into weakness. Zoetis itself remains fundamentally sound—the company is profitable, generating growing revenue, and trades at a reasonable valuation multiple—so this buying into a pullback in an otherwise healthy business is what makes the trade noteworthy.

Director Bisaro Paul makes first open-market purchase of 2,000 shares as ZTS trades well below 52-week highs; part of 3-insider buying cluster in 14 days.

Director Bisaro Paul purchased 2,000 shares at the market, marking his first open-market purchase in the 36-month record — prior activity consisted entirely of stock-based compensation transactions. The purchase occurred as Zoetis trades substantially below its 52-week high and has declined significantly over the past quarter, but the company remains profitable with stable revenue growth and a reasonable valuation multiple. Notably, this purchase is part of a cluster of insider buying activity: three insiders acquired shares within a 14-day window, suggesting interest in the stock at current levels. Paul's decision to commit personal capital at a time when the stock faces headwinds distinguishes this from his typical compensation-driven filings.

Director Michael McCallister makes first open-market purchase of ZTS shares as stock trades well below 52-week highs.

Michael McCallister, a director at Zoetis, purchased shares on the open market for the first time, marking a notable shift from his prior Form 4 activity which consisted entirely of stock-based compensation exercises. The purchase occurs while ZTS trades substantially below its 52-week high, having declined significantly over recent months. The company remains profitable with steady fundamentals, suggesting McCallister is choosing to deploy personal capital into a company that still generates consistent earnings but has lost considerable value from its recent peaks. This is the type of entry point that typically attracts insider buying — weakness in a fundamentally sound business — and the fact that McCallister broke from his historical pattern of compensation-driven transactions to make a discretionary purchase underscores deliberate action on his part.

CEO Kristin C Peck sold 20,000 shares of ZTS for $2.5M at blended $127.05, retaining 101.3K shares

Kristin C Peck, CEO of Zoetis Inc., executed 2 separate sales on 2026-02-17, totaling 20,000 shares for $2,540,964.28 at a blended average price of $127.05—above the current price of $125.56. The sale reduced her holdings by 16.5%, leaving her with 101,337 shares post-transaction. Historically, her prior 5 sales at Zoetis have yielded mixed results: 3 of 5 were well-timed at the 90-day mark (negative post-sale returns), but 2 were poorly timed, suggesting no consistent pattern of foresight at this specific ticker. Across her broader cross-ticker track record, her 5 prior sells averaged a 0.4% 90-day return with a 60.00% well-timed rate, indicating moderate but not exceptional timing discipline. The stock is currently -27.8% from its 52-week high of $173.88, and the company's P/E of 18.68 and annual revenue growth of 2.3% suggest a mature, moderately valued business.

ZTS EVP Polzer sells 3,477 shares (-51.7% of holdings) at $177.46; stock down -12.2% from 52-week high

Robert J Polzer, Executive Vice President of Zoetis Inc., sold 3,477 shares on 2024-11-25 at $177.46, reducing his holdings from 6,726 shares to 3,249 shares—a 51.7% reduction in position size. The transaction occurred at a price $1.76 above the current market price of $175.70, and the stock is currently 12.2% below its 52-week high of $200.09. The sale represents a material reduction in his equity stake and occurs within a company trading at a P/E of 32.60 and with recent quarterly revenue of $2.4B and net income of $682.0M. Without scheduled trading plan disclosure or additional pattern context, this substantial portfolio reduction warrants observation of whether it reflects portfolio management or shifts in insider positioning at ZTS.